Dr. Reddy's launches generic LyricaThe Lyrica capsules brand had a market value of roughly $5.5 billion for the most recent 12 months ended May 2019. Glenmark gets FDA OK for generic VytorinVytorin tablets had a market value of approximately $92.4 million for the 12-month period ended April 2019. Zydus Cadila intros generic Rozerem Zydus Cadila's generic Rozerem is used to treat insomnia that is associated with having trouble falling asleep. Mylan, Pfizer’s Upjohn to merge, form new company Pfizer is set to combine its off-patent and generics business with Mylan in an all-stock deal that will create a new company led by executives from both companies. Camber launches generic Tessalon The product is used to treat coughs caused by the common cold and other breathing problems. FDA gives tentative nod to Alembic’s generic Farxiga Dapagliflozin tablets had a market value of about $1.7 billion for the 12 months ended December 2018, according to IQVIA. Pfizer gets FDA nod for biosimilar Rituxan Pfizer's Ruxience is a biosimilar to Rituxan indicated to treat certain cancers and autoimmune conditions. Dr. Reddy's launches generic Rozerem The Rozerem brand had a market value of approximately $91.3 million for the year ended May 2019, according to IQVIA. Nine generic firms get FDA approval for generic Lyrica Pregabalin capsules had a market value of about $5.4 billion for the 12 months ended May 31, 2019, according to IQVIA. Amneal launches generic Ery-Tab Amneal's generic Ery-Tab is the first generic of the branded product. First Previous 182 183 184 185 186 Next Last
